Novartis AG (NYSE:NVS) Shares Sold by BSW Wealth Partners

BSW Wealth Partners trimmed its holdings in shares of Novartis AG (NYSE:NVS) by 7.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,169 shares of the company’s stock after selling 558 shares during the period. BSW Wealth Partners’ holdings in Novartis were worth $698,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of NVS. Steigerwald Gordon & Koch Inc. increased its holdings in shares of Novartis by 4.8% in the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock worth $241,000 after acquiring an additional 95 shares during the period. Centaurus Financial Inc. increased its stake in shares of Novartis by 1.7% in the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock valued at $659,000 after purchasing an additional 98 shares during the period. FLC Capital Advisors raised its holdings in shares of Novartis by 4.4% during the third quarter. FLC Capital Advisors now owns 2,366 shares of the company’s stock valued at $272,000 after buying an additional 100 shares during the last quarter. Clear Harbor Asset Management LLC grew its holdings in Novartis by 2.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock worth $509,000 after buying an additional 100 shares in the last quarter. Finally, Allen Wealth Management LLC increased its position in Novartis by 1.8% in the 3rd quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock valued at $666,000 after acquiring an additional 100 shares during the period. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Stock Performance

NYSE:NVS opened at $101.85 on Wednesday. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92. The firm has a market cap of $208.19 billion, a price-to-earnings ratio of 11.83, a price-to-earnings-growth ratio of 1.42 and a beta of 0.57. The company has a 50-day moving average of $100.10 and a 200-day moving average of $108.64. The company has a current ratio of 1.11, a quick ratio of 0.90 and a debt-to-equity ratio of 0.55.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.12. The business had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. Novartis had a return on equity of 34.80% and a net margin of 35.96%. During the same period last year, the company posted $1.74 EPS. Analysts forecast that Novartis AG will post 7.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on NVS shares. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. BMO Capital Markets boosted their price target on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Finally, HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Two research analysts have rated the stock with a sell rating and six have given a hold rating to the company. According to MarketBeat, Novartis presently has a consensus rating of “Hold” and a consensus target price of $123.38.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.